PMID- 19718479
OWN - NLM
STAT- MEDLINE
DCOM- 20091125
LR  - 20220318
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 102
IP  - 3
DP  - 2009 Sep
TI  - Levels of von Willebrand factor antigen and von Willebrand factor cleaving 
      protease (ADAMTS13) activity predict clinical events in chronic heart failure.
PG  - 573-80
LID - 10.1160/TH09-01-0036 [doi]
AB  - Decreased activity of ADAMTS13, the von Willebrand factor (VWF) cleaving 
      protease, was recently reported in cardiovascular diseases and in hepatic 
      failure. Chronic heart failure (CHF) is characterised by abnormalities of left 
      ventricular function accompanied by the failure of the liver and dysregulation of 
      endothelial activation. Therefore, the aim of our study was to measure ADAMTS13 
      activity in CHF, and determine the prognostic value of VWF and ADAMTS13 on major 
      clinical events in CHF. ADAMTS13 activity (measured by FRETS-VWF73 substrate) was 
      decreased in CHF (n = 152, left ventricular ejection fraction <45%), and it 
      correlated negatively with B-type natriuretic peptide (BNP) NYHA (New York Heart 
      Association) classes, markers of synthetic capacity of the liver and endothelial 
      dysfunction (all p < 0.005). Both, high VWF:Ag levels (hazard ratio [HR] 1.52, 
      95% confidence interval [CI] 1.189-1.943), and low ADAMTS13/VWF:Ag ratios (HR 
      0.70, 95% CI 0.58-0.84) independently and significantly predicted short-term (1 
      year follow-up) clinical adverse events in heart failure (HF). Decreased activity 
      of ADAMTS13 with concomitant high VWF:Ag levels is a significant independent 
      predictor of clinical events in CHF. The levels of the two molecules may 
      integrate the impaired synthetic capacity of the liver and the disturbed 
      endothelial regulation and can therefore be a useful tool to predict clinical 
      events in CHF.
FAU - Gombos, Timea
AU  - Gombos T
AD  - IIIrd Department of Internal Medicine, Semmelweis University, H-1125 Budapest, 
      Hungary.
FAU - Mako, Veronika
AU  - Mako V
FAU - Cervenak, Laszlo
AU  - Cervenak L
FAU - Papassotiriou, Jana
AU  - Papassotiriou J
FAU - Kunde, Jan
AU  - Kunde J
FAU - Harsfalvi, Jolan
AU  - Harsfalvi J
FAU - Forhecz, Zsolt
AU  - Forhecz Z
FAU - Pozsonyi, Zoltan
AU  - Pozsonyi Z
FAU - Borgulya, Gabor
AU  - Borgulya G
FAU - Janoskuti, Livia
AU  - Janoskuti L
FAU - Prohaszka, Zoltan
AU  - Prohaszka Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Biomarkers)
RN  - 0 (von Willebrand Factor)
RN  - EC 3.4.24.- (ADAM Proteins)
RN  - EC 3.4.24.87 (ADAMTS13 Protein)
RN  - EC 3.4.24.87 (ADAMTS13 protein, human)
SB  - IM
MH  - ADAM Proteins/*biosynthesis
MH  - ADAMTS13 Protein
MH  - Aged
MH  - Biomarkers/metabolism
MH  - Chronic Disease
MH  - Cohort Studies
MH  - Endothelium, Vascular/pathology
MH  - Female
MH  - Heart Failure/*blood/diagnosis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Models, Biological
MH  - Risk
MH  - Treatment Outcome
MH  - von Willebrand Factor/*biosynthesis
EDAT- 2009/09/01 06:00
MHDA- 2009/12/16 06:00
CRDT- 2009/09/01 09:00
PHST- 2009/09/01 09:00 [entrez]
PHST- 2009/09/01 06:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - 09-01-0036 [pii]
AID - 10.1160/TH09-01-0036 [doi]
PST - ppublish
SO  - Thromb Haemost. 2009 Sep;102(3):573-80. doi: 10.1160/TH09-01-0036.